Abstract 12P
Background
The tumor-infiltrating lymphocytes (TILs), especially stromal TILs, have showed a prognostic role in human epidermal growth factor receptor 2 (HER2)-positive and triple negative breast cancer. Stromal TILs are associated with higher pathological complete remission (pCR) rates after neoadjuvant chemotherapy. However, the relation between stromal TILs in primary breast cancer and axillary nodal metastasis remains uncertain.
Methods
A retrospective review of pathological reports of 763 patients with breast infiltrating ductal carcinoma (IDC) was conducted. The gene expression and clinical data of 662 IDC cases were downloaded from the TCGA database. In silico analysis was based on the gene expression data. The “Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data” (ESTIMATE) algorithm was used to calculate the stromal and immune scores in N0 and N+ cases.
Results
In HER2+ breast cancer, the fractions of stromal TILs are higher than 30% (37.57% versus 19.67%, P=0.01) and 40% (25.97% vs 8.20%, P=0.003) in lymph node negative cases comparing to nodal metastasis cases. The fractions of stromal TILs in HER2- breast cancer showed no difference between N0 and N+ stage cases. We further compare the fractions of stromal TILs between N0 and N+ cases in different subtypes of breast cancer cases. The stromal TILs (%) is only higher in primary tumors of N0 HER2 amplified breast cancer cases than N+ cases (P=0.014). The stromal TILs (%) of primary tumors are similar between N0 and N+ cases in Luminal A (hormone receptor (HR)+/HER2-) (P=0.261), Luminal B (HR+/HER2+) (P=0.838) and triple negative (HR-/HER2-) subtypes (P=0.456). The primary tumors immune scores of N0 and N+ cases show no significantly difference in HER2+/- breast cancer. The stromal scores of N+ cases are higher than N0 cases in HER2+ breast cancer (P=0.015). The stromal scores are similar between N0 and N+ cases in HER2- breast cancer. Table: 12P
Stromal TILs(%) | N0(cases) | % | N+(cases) | % | P value | |
Her2+ | 0-9 | 72 | 39.78 | 28 | 45.90 | |
10- | 109 | 60.22 | 33 | 54.10 | ||
0.401 | ||||||
0-19 | 101 | 55.80 | 40 | 65.57 | ||
20- | 80 | 44.75 | 21 | 34.43 | ||
0.181 | ||||||
0-29 | 113 | 62.43 | 49 | 80.33 | ||
30- | 68 | 37.57 | 12 | 19.67 | ||
0.01 | ||||||
0-39 | 134 | 74.03 | 56 | 91.8 | ||
40- | 47 | 25.97 | 5 | 8.2 | ||
0.003 | ||||||
Stromal TILs(%) | N0(cases) | % | N+(cases) | % | P value | |
Her2+ | 0-9 | 219 | 59.03 | 83 | 55.70 | |
10- | 152 | 40.97 | 66 | 44.30 | ||
0.487 | ||||||
0-19 | 286 | 77.09 | 115 | 77.18 | ||
20- | 85 | 22.91 | 34 | 22.82 | ||
0.982 | ||||||
0-29 | 313 | 84.37 | 124 | 83.22 | ||
30- | 58 | 15.63 | 25 | 16.78 | ||
0.747 | ||||||
0-39 | 335 | 90.30 | 135 | 90.60 | ||
40- | 36 | 9.70 | 14 | 9.4 | ||
0.914 |
Conclusions
The higher fraction of stromal TILs is negatively related to lymph nodes metastasis in her2-positive breast cancer. Since the stromal fraction of tumor tissue may be higher in HER2+ N+ breast cancer, it also tends to be associated with nodal metastasis. In total, it is not the absolute quantity of immune cells, but the relative quantity of TILs in tumor stroma (which we evaluated as stromal TILs (%)) makes a vital role in predicting nodal stage of HER2 amplified IDC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Weiqichun.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session